VBL Therapeutics : Our innovative platform and promising compounds for the treatment of immune-inflammatory diseases and cancer

VBL Therapeutics is an innovative, clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. Currently available therapies are limited in their ability to adequately treat serious and sometimes life-threatening diseases. As a result, VBL was founded to create new treatment options that address this underlying unmet medical need.


VBL’s first program pioneered the Lecinoxoid class of oral anti-inflammatory agents.  VB-201 is a proprietary, first-in-class, orally-available, specific innate immunity disease-modifying medicine in development for the effective treatment of chronic immuno-inflammatory diseases. VB-201 offers the potential to deliver long-term control of a spectrum of immuno-inflammatory diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis, and atherosclerosis. The compound is positioned to work as a standalone treatment or as part of combination therapy.


VB-201 has successfully completed five Phase 1 clinical trials and two Phase 2 pilot and exploratory clinical trials. In addition to providing human, clinical proof-of-concept for the control of chronic inflammatory disease in psoriatic patients, VB-201 also demonstrated a significant reduction of atherosclerotic plaque inflammation, as well as an excellent safety and tolerability profile.


VBL’s second program has yielded a proprietary Vascular Targeting System (VTS™) technology platform that has produced VB-111, a first-in-class, highly-targeted, antiangiogenic biological agent for the treatment of cancer. This compound has been advanced into tumor-specific, repeat-dose trials including an open-label Phase 2 trials in glioblastoma multiforme (GBM), thyroid cancer, renal cell carcinoma (RCC) and neuroendocrine tumor (NEC).


Both compounds target multibillion dollar markets with unmet need for safe and well-tolerated treatments, and provide differentiation from current or proposed treatments.


Founded in 2000, VBL is based in Tel Aviv, Israel. The company has more than 70 granted patents and more than 110 applications pending.


Both comments and pings are currently closed.

Comments are closed.